Pharmaceutical company Dr. Reddy's Laboratories Ltd (NSE:DRREDDY) (NYSE:RDY) reported on Friday the availability of Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU (carmustine for injection) in the US market.
The company revealed Carmustine for Injection, USP is a therapeutic equivalent generic version of BiCNU (carmustine for injection), which is approved by the US Food and Drug Administration (USFDA).
In addition, Carmustine for Injection, USP is a lyophilized powder available as a package which includes a single-dose vial containing 100 mg Carmustine USP and a vial containing 3 ml sterile diluent, stated the company.
According to IQVIA Health, the BiCNU brand and generic market had U.S. sales of approximately USD19.4m MAT for the most recent 12 months ending in August 2021. iCNU is a trademark owned or licensed by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Carmustine is used to treat cancer of lymphatic system, brain and certain types of cancers of bone marrow. It may be used to treat other types of cancer. It can be used alone, or together with certain other medicines as part of combination chemotherapy, added the company.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT